METHOD OF TREATMENT OF LUMINAL SUBTYPE OF BREAST CANCER N1 IN POSTMENOPAUSAL PERIOD Russian patent published in 2017 - IPC A61N5/10 A61K31/138 A61K31/4196 A61K31/675 A61K31/727 A61P35/00 A61B10/02 G01N33/48 

FIELD: medicine.

SUBSTANCE: for the treatment of the luminal subtype of breast cancer N1 in the postmenopausal period, estrogen receptors are determined, the total diameter of metastases D in axillary lymph nodes and the average number of metastatic cells K whose nuclei express estrogen receptors in them. If identifying 2≤D<10 mm and the value of K exceeding 1%, radiotherapy is carried out according to the chosen treatment regimen, and after its completion, combined administration of tamoxifen and a nonselective beta-blocker is carried out daily in therapeutic doses for 1-5 years. If D≥10 mm is detected and at a value of K≥33% consistently perform adjuvant chemotherapy with simultaneous subcutaneous administration of fragin at a daily dose of 2500 ME daily, then radiotherapy is performed according to the chosen treatment regimen, and then hormone therapy with aromatase inhibitor is carried out for 5-7 years. If D≥10 mm is detected and with a value of K<33%, concurrent chemoradiotherapy and hormone therapy are performed, concomitantly with chemotherapy subcutaneous injection of fragmine at a dose of 5000 ME daily, and as an hormone inhibitor, an aromatase inhibitor is used for 7-10 years.

EFFECT: method provides an opportunity to undergo a shorter period of treatment, in some cases to preserve the ability to work during it, to save the patient from possible complications while ensuring high effectiveness of therapy.

3 ex